Human KLK1 ELISA kit (4X96T)
- Known as:
- Human KLK1 Enzyme-linked immunosorbent assay test reagent (4X96T)
- Catalog number:
- lf-ek50754
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Abfrontier
- Gene target:
- Human KLK1 ELISA kit (4X96T)
Related genes to: Human KLK1 ELISA kit (4X96T)
- Gene:
- KLK1 NIH gene
- Name:
- kallikrein 1
- Previous symbol:
- -
- Synonyms:
- Klk6
- Chromosome:
- 19q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-27
- Date modifiied:
- 2016-11-15
- Gene:
- KLKP1 NIH gene
- Name:
- kallikrein pseudogene 1
- Previous symbol:
- -
- Synonyms:
- YKLK1, PsiKLK1, KLK31P
- Chromosome:
- 19q13.33
- Locus Type:
- pseudogene
- Date approved:
- 2005-08-04
- Date modifiied:
- 2014-03-18
Related products to: Human KLK1 ELISA kit (4X96T)
Related articles to: Human KLK1 ELISA kit (4X96T)
- KLK4::KLKP1 fusion is a recently described pseudogene that is enriched in prostate cancer (PCa). This new biomarker has not been characterized in the Middle Eastern population. - Source: PubMed
Publication date: 2022/08/18
Bakker AndreaSlack Jonathan CPalanisamy NallaCarskadon ShannonGhosh SunitaKhalifeh IbrahimBismar Tarek A - The human kallikrein-related peptidase 4 (KLK4) and the transcribed pseudogene KLKP1 are reported to be highly expressed in the prostate. When trying to clone transcripts of KLKP1, we partly failed. Instead, we identified an androgen-regulated transcript, KLK4T2, which appeared to be a splice variant of KLK4 that also contained exons of KLKP1. Expression analysis of KLK4, KLK4T2, and KLKP1 transcripts in prostate cancer cell lines showed high levels of KLKP1 transcripts in the nucleus and in unfractionated cell extract, whereas it was almost completely absent in the cytoplasmatic fraction. This was in contrast to KLK4 and KLK4T2, which displayed high to moderate levels in the cytoplasm. In patient cohorts we found significantly higher expression of both KLK4T2 and KLK4 in benign prostatic hyperplasia compared to both primary prostate cancer and bone metastasis. Analysis of tissue panels demonstrated the highest expression of KLK4T2 in the prostate, but in contrast to the classical KLK4, relatively high levels were also found in placenta. So far, the function of KLK4T2 is still to be explored, but the structure of the translation product indicated that it generates a 17.4 kDa intracellular protein with possible regulatory function. - Source: PubMed
Publication date: 2021/12/01
Lundwall ÅkeYlitalo Erik BovinderWikström PernillaBrattsand Maria - We present the functional characterization of a pseudogene associated recurrent gene fusion in prostate cancer. The fusion gene KLK4-KLKP1 is formed by the fusion of the protein coding gene KLK4 with the noncoding pseudogene KLKP1. Screening of a cohort of 659 patients (380 Caucasian American; 250 African American, and 29 patients from other races) revealed that the KLK4-KLKP1 is expressed in about 32% of prostate cancer patients. Correlative analysis with other ETS gene fusions and SPINK1 revealed a concomitant expression pattern of KLK4-KLKP1 with ERG and a mutually exclusive expression pattern with SPINK1, ETV1, ETV4, and ETV5. Development of an antibody specific to KLK4-KLKP1 fusion protein confirmed the expression of the full-length KLK4-KLKP1 protein in prostate tissues. The in vitro and in vivo functional assays to study the oncogenic properties of KLK4-KLKP1 confirmed its role in cell proliferation, cell invasion, intravasation, and tumor formation. Presence of strong ERG and AR binding sites located at the fusion junction in KLK4-KLKP1 suggests that the fusion gene is regulated by ERG and AR. Correlative analysis of clinical data showed an association of KLK4-KLKP1 with lower preoperative PSA values and in young men (<50 years) with prostate cancer. Screening of patient urine samples showed that KLK4-KLKP1 can be detected noninvasively in urine. Taken together, we present KLK4-KLKP1 as a class of pseudogene associated fusion transcript in cancer with potential applications as a biomarker for routine screening of prostate cancer. - Source: PubMed
Publication date: 2019/08/22
Chakravarthi Balabhadrapatruni VskDedigama-Arachchige PavithraCarskadon ShannonSundaram Shanker KalyanaLi JiaWu Kuan-Han HankChandrashekar Darshan ShimogaPeabody James OStricker HansHwang ClaraChitale Dhananjay AWilliamson Sean RGupta Nilesh SNavone Nora MRogers CraigMenon ManiVarambally SooryanarayanaPalanisamy Nallasivam - The kallikrein-related (KLK) serine protease, prostate specific antigen is the current marker for prostate cancer (PCa). Other members of the KLK family are also emerging as potential adjunct biomarkers for this disease. Our aim was to identify and characterize novel KLK-related genes with potential as PCa bio-markers. - Source: PubMed
Kaushal AneelMyers Stephen ADong YingLai JohnTan Olivia LBui Loan THunt Melanie LDigby Matthew RSamaratunga HemamaliGardiner Robert AClements Judith AHooper John D - Fifteen human tissue kallikrein (KLK) genes have been identified as a cluster on chromosome 19. KLK expression is associated with various human diseases including cancers. Noncoding RNAs such as PCA3/DD3 and PCGEM1 have been identified in prostate cancer cells. - Source: PubMed
Lu WeiZhou DaixingGlusman GustavoUtleg Angelita GWhite James TNelson Peter SVasicek Thomas JHood LeroyLin Biaoyang